{"id":"other-combination-anti-cancer-therapies","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Immune-related adverse events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Combination anti-cancer therapies work by targeting multiple pathways or mechanisms simultaneously to improve efficacy and overcome resistance. Hoffmann-La Roche develops various combinations that may pair chemotherapy with targeted agents, immunotherapies with targeted drugs, or multiple immunotherapies to enhance anti-tumor activity.","oneSentence":"This is a category descriptor for multiple combination anti-cancer therapies rather than a single drug, typically involving synergistic use of two or more oncologic agents.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:25:02.847Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various solid tumors and hematologic malignancies (specific combinations vary by pipeline program)"}]},"trialDetails":[{"nctId":"NCT06514261","phase":"PHASE1","title":"Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-12-18","conditions":"Acute Myeloid Leukemia","enrollment":45},{"nctId":"NCT07024784","phase":"PHASE2","title":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-07-30","conditions":"Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer","enrollment":377},{"nctId":"NCT05372640","phase":"PHASE1","title":"Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma","enrollment":45},{"nctId":"NCT05711615","phase":"PHASE1","title":"Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-06","conditions":"Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma","enrollment":30},{"nctId":"NCT06287775","phase":"PHASE1, PHASE2","title":"Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-04-08","conditions":"Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":45},{"nctId":"NCT06953323","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Wigen Biomedicine Technology (Shanghai) Co., Ltd.","startDate":"2025-07-10","conditions":"Advanced Solid Tumor","enrollment":86},{"nctId":"NCT07082803","phase":"PHASE1","title":"TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas","status":"RECRUITING","sponsor":"Treeline Biosciences, Inc.","startDate":"2025-06-23","conditions":"Lymphoma, Lymphoma, Non Hodgkin","enrollment":180},{"nctId":"NCT04670679","phase":"PHASE1","title":"A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erasca, Inc.","startDate":"2020-12-15","conditions":"Advanced or Metastatic Solid Tumors","enrollment":90},{"nctId":"NCT06580938","phase":"PHASE1","title":"A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer","status":"TERMINATED","sponsor":"Pfizer","startDate":"2024-11-11","conditions":"Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma","enrollment":4},{"nctId":"NCT07218003","phase":"PHASE1","title":"A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4","status":"ENROLLING_BY_INVITATION","sponsor":"Rondo Therapeutics","startDate":"2025-11-17","conditions":"Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer","enrollment":149},{"nctId":"NCT05143970","phase":"PHASE1","title":"A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Institut Paoli-Calmettes","startDate":"2022-01-21","conditions":"Metastatic Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer","enrollment":27},{"nctId":"NCT07174336","phase":"PHASE3","title":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-22","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":920},{"nctId":"NCT05789082","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-06-20","conditions":"Non-Small Cell Lung Cancer","enrollment":320},{"nctId":"NCT07155226","phase":"PHASE1, PHASE2","title":"Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-09","conditions":"Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes","enrollment":84},{"nctId":"NCT05098132","phase":"PHASE1, PHASE2","title":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","status":"RECRUITING","sponsor":"Synthekine","startDate":"2022-01-25","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC","enrollment":364},{"nctId":"NCT07239596","phase":"PHASE1, PHASE2","title":"Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-01-06","conditions":"Advanced Renal Cell Carcinoma","enrollment":139},{"nctId":"NCT04662580","phase":"PHASE1","title":"ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-05-03","conditions":"Metastatic Prostate Cancer","enrollment":183},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT04970901","phase":"PHASE1","title":"A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)","status":"RECRUITING","sponsor":"ADC Therapeutics S.A.","startDate":"2022-06-17","conditions":"B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma","enrollment":200},{"nctId":"NCT04585750","phase":"PHASE1, PHASE2","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","status":"RECRUITING","sponsor":"PMV Pharmaceuticals, Inc","startDate":"2020-10-29","conditions":"Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer","enrollment":300},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT07070232","phase":"PHASE1, PHASE2","title":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-08-12","conditions":"Advanced Solid Tumor","enrollment":980},{"nctId":"NCT07350850","phase":"PHASE2","title":"A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-25","conditions":"PCNSL, Primary Central Nervous System Lymphoma","enrollment":110},{"nctId":"NCT06619587","phase":"PHASE1","title":"A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2024-11-14","conditions":"Solid Tumor","enrollment":410},{"nctId":"NCT06279130","phase":"PHASE2, PHASE3","title":"Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-01-29","conditions":"Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors","enrollment":133},{"nctId":"NCT05526924","phase":"PHASE1","title":"Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2023-03-07","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma","enrollment":30},{"nctId":"NCT07448116","phase":"PHASE1, PHASE2","title":"Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2026-01-31","conditions":"Solid Advanced Tumor","enrollment":164},{"nctId":"NCT04895748","phase":"PHASE1","title":"DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-30","conditions":"Carcinoma, Renal Cell","enrollment":40},{"nctId":"NCT04238819","phase":"PHASE1, PHASE2","title":"A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-11-09","conditions":"Relapsed Solid Tumor, Refractory Solid Tumor","enrollment":47},{"nctId":"NCT07204340","phase":"PHASE1","title":"TLN-372 in Advanced KRAS Mutant Solid Tumors","status":"RECRUITING","sponsor":"Treeline Biosciences, Inc.","startDate":"2025-09-29","conditions":"KRAS Mutant Solid Tumors","enrollment":240},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT03942328","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-19","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":85},{"nctId":"NCT05081609","phase":"PHASE1, PHASE2","title":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascendis Pharma Oncology Division A/S","startDate":"2022-01-11","conditions":"Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":320},{"nctId":"NCT05090566","phase":"PHASE2","title":"MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-10-27","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT06546553","phase":"PHASE1","title":"A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2024-09-06","conditions":"Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck","enrollment":10},{"nctId":"NCT06034470","phase":"PHASE1","title":"Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-12-18","conditions":"Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome","enrollment":30},{"nctId":"NCT06959706","phase":"PHASE1","title":"Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Tagworks Pharmaceuticals BV","startDate":"2025-05-07","conditions":"Advanced Solid Tumors","enrollment":50},{"nctId":"NCT07424664","phase":"PHASE2","title":"A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-03-15","conditions":"Uterine Cervical Neoplasms, Recurrent; Uterine Cervical Neoplasms, Metastatic; Vulvar Neoplasms; Vaginal Neoplasms","enrollment":30},{"nctId":"NCT06625593","phase":"PHASE1","title":"A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-12-09","conditions":"Advanced Solid Tumor","enrollment":168},{"nctId":"NCT04868877","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merus B.V.","startDate":"2021-04-28","conditions":"Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma","enrollment":194},{"nctId":"NCT05882734","phase":"PHASE1, PHASE2","title":"Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)","status":"ACTIVE_NOT_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2023-09-13","conditions":"Non-Small Cell Lung Cancer","enrollment":61},{"nctId":"NCT04973163","phase":"PHASE1","title":"A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2021-09-09","conditions":"Solid Tumors, KRAS Mutation","enrollment":30},{"nctId":"NCT06820957","phase":"PHASE2, PHASE3","title":"Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-11-10","conditions":"CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma, Metastatic High Grade Sarcoma","enrollment":437},{"nctId":"NCT02274779","phase":"PHASE2","title":"Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer","status":"COMPLETED","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2014-08-20","conditions":"Prostate Cancer","enrollment":74},{"nctId":"NCT02320435","phase":"PHASE3","title":"A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2015-02-02","conditions":"Solid Tumors","enrollment":154},{"nctId":"NCT07407933","phase":"PHASE1, PHASE2","title":"A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2026-03","conditions":"Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma","enrollment":118},{"nctId":"NCT04449874","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2020-07-29","conditions":"Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors","enrollment":498},{"nctId":"NCT02499328","phase":"PHASE1, PHASE2","title":"Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-06","conditions":"Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck","enrollment":340},{"nctId":"NCT04577014","phase":"PHASE1, PHASE2","title":"Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-09-29","conditions":"Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma","enrollment":98},{"nctId":"NCT03851614","phase":"PHASE2","title":"Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2019-04-08","conditions":"Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma","enrollment":90},{"nctId":"NCT07387081","phase":"PHASE2","title":"Phase II Study of LM-24C5","status":"RECRUITING","sponsor":"LaNova Medicines Limited","startDate":"2025-12-15","conditions":"Advanced Solid Tumor Cancer","enrollment":130},{"nctId":"NCT05489887","phase":"PHASE2","title":"Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma","status":"RECRUITING","sponsor":"Giselle Sholler","startDate":"2022-09-14","conditions":"Neuroblastoma","enrollment":93},{"nctId":"NCT01391962","phase":"PHASE2","title":"Sunitinib or Cediranib for Alveolar Soft Part Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-18","conditions":"Sarcoma, Alveolar Soft Part","enrollment":34},{"nctId":"NCT06710847","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-12-13","conditions":"Neoplasms, Colorectal, Solid Tumor, Colon Cancer","enrollment":14},{"nctId":"NCT02143466","phase":"PHASE1","title":"AZD9291 in Combination With Ascending Doses of Novel Therapeutics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-08-05","conditions":"Advanced Non Small Cell Lung Cancer","enrollment":344},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT07376512","phase":"","title":"Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis","status":"NOT_YET_RECRUITING","sponsor":"Centre Georges Francois Leclerc","startDate":"2026-03-01","conditions":"Non-Small Cell Lung Cancer, Melanoma (Skin Cancer)","enrollment":378},{"nctId":"NCT04028063","phase":"PHASE2","title":"Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2020-01-28","conditions":"Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma","enrollment":65},{"nctId":"NCT03156114","phase":"PHASE1","title":"This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-06-13","conditions":"Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":172},{"nctId":"NCT05327530","phase":"PHASE2","title":"A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)","status":"ACTIVE_NOT_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-08-17","conditions":"Locally Advanced or Metastatic Urothelial Carcinoma","enrollment":256},{"nctId":"NCT05137054","phase":"PHASE1","title":"A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-17","conditions":"Multiple Myeloma","enrollment":317},{"nctId":"NCT07354984","phase":"PHASE2","title":"A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-01","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT05584670","phase":"PHASE1, PHASE2","title":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Sanofi","startDate":"2022-11-29","conditions":"Solid Tumor","enrollment":542},{"nctId":"NCT07351565","phase":"PHASE1","title":"Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Chang Chen","startDate":"2026-01-10","conditions":"Non-Small Cell Lung Cancer","enrollment":22},{"nctId":"NCT07231458","phase":"PHASE1","title":"A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies","status":"RECRUITING","sponsor":"Abalos Therapeutics GmbH","startDate":"2025-10-14","conditions":"Advanced Solid Tumors","enrollment":27},{"nctId":"NCT05353257","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2022-05-17","conditions":"Limited-Stage Small Cell Lung Cancer","enrollment":511},{"nctId":"NCT04526899","phase":"PHASE2","title":"A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2021-05-19","conditions":"Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma","enrollment":184},{"nctId":"NCT07307443","phase":"PHASE2","title":"A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Zhijie Wang","startDate":"2026-02-01","conditions":"SMARCA4-Deficient Tumor, Locally Advanced or Metastatic Lung Cancer","enrollment":28},{"nctId":"NCT03993379","phase":"PHASE2","title":"PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors","status":"TERMINATED","sponsor":"CytomX Therapeutics","startDate":"2019-11-20","conditions":"Solid Tumor, Unresectable or Metastatic Melanoma","enrollment":3},{"nctId":"NCT00781612","phase":"PHASE2","title":"A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2008-10-16","conditions":"Neoplasm Metastasis","enrollment":720},{"nctId":"NCT03610711","phase":"PHASE1, PHASE2","title":"REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-03-06","conditions":"Gastroesophageal Cancer, Immune Checkpoint Inhibition","enrollment":21},{"nctId":"NCT03433898","phase":"EARLY_PHASE1","title":"This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-02-23","conditions":"Neoplasms","enrollment":146},{"nctId":"NCT05270213","phase":"PHASE1","title":"Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Riboscience, LLC.","startDate":"2022-07-11","conditions":"Advanced Cancer","enrollment":164},{"nctId":"NCT05860296","phase":"PHASE1, PHASE2","title":"Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers","status":"TERMINATED","sponsor":"SignalChem Lifesciences Corporation","startDate":"2023-05-31","conditions":"Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic","enrollment":36},{"nctId":"NCT03388632","phase":"PHASE1","title":"Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-05","conditions":"Metastatic Solid Tumors, Treatment-Refractory Cancers","enrollment":31},{"nctId":"NCT06714357","phase":"PHASE2","title":"ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2025-03-12","conditions":"Colorectal Cancer Metastatic","enrollment":130},{"nctId":"NCT06121505","phase":"PHASE2","title":"Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-03-01","conditions":"Lung Squamous Cell Carcinoma","enrollment":114},{"nctId":"NCT06492759","phase":"PHASE2","title":"High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-01-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":29},{"nctId":"NCT03534947","phase":"PHASE2","title":"A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma","status":"COMPLETED","sponsor":"Melanoma Institute Australia","startDate":"2019-07-23","conditions":"Basal Cell Carcinoma, Basal Cell Carcinoma of Skin, Site Unspecified, Skin Cancer","enrollment":16},{"nctId":"NCT05322577","phase":"PHASE1, PHASE2","title":"A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-05-17","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":72},{"nctId":"NCT05664971","phase":"PHASE1, PHASE2","title":"JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-02-09","conditions":"Advanced Lung Cancer","enrollment":119},{"nctId":"NCT07229729","phase":"PHASE2","title":"A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2025-11-24","conditions":"Non-small Cell Lung Cancer","enrollment":300},{"nctId":"NCT03307785","phase":"PHASE1","title":"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-10-12","conditions":"Neoplasms, Metastatic Cancer, Advanced Cancer","enrollment":60},{"nctId":"NCT06126731","phase":"PHASE1, PHASE2","title":"Combination Study of Antibiotics With Enzalutamide (PROMIZE)","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2023-11-02","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":39},{"nctId":"NCT03284957","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-09-20","conditions":"Breast Cancer","enrollment":136},{"nctId":"NCT07241767","phase":"PHASE2","title":"A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-11-12","conditions":"Lung Cancer","enrollment":200},{"nctId":"NCT07071103","phase":"PHASE2","title":"Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors","status":"RECRUITING","sponsor":"Chuangzhen Chen","startDate":"2025-09-26","conditions":"Radiotherapy, Metastatic Solid Cancers, Immune Checkpoint Blockade","enrollment":48},{"nctId":"NCT05786924","phase":"PHASE1, PHASE2","title":"Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies","status":"RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2023-04-18","conditions":"Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis","enrollment":554},{"nctId":"NCT07175220","phase":"PHASE2","title":"Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-10-09","conditions":"Locally Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":200},{"nctId":"NCT07229599","phase":"PHASE1, PHASE2","title":"A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer","status":"RECRUITING","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","startDate":"2025-05-09","conditions":"Advanced Lung Cancer","enrollment":300},{"nctId":"NCT04819373","phase":"PHASE2","title":"BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors","status":"COMPLETED","sponsor":"Eikon Therapeutics","startDate":"2021-08-30","conditions":"Tumor, Solid","enrollment":1},{"nctId":"NCT05142189","phase":"PHASE1","title":"Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2022-06-17","conditions":"Non-Small Cell Lung Cancer","enrollment":280},{"nctId":"NCT05434234","phase":"PHASE1, PHASE2","title":"A Study of YL201 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2022-05-25","conditions":"Advanced Solid Tumor","enrollment":312},{"nctId":"NCT03334617","phase":"PHASE2","title":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-12-18","conditions":"Non-Small Cell Lung Cancer","enrollment":528},{"nctId":"NCT03217747","phase":"PHASE1, PHASE2","title":"Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-02","conditions":"Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma, Malignant Solid Neoplasm","enrollment":173},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT07111520","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-09-22","conditions":"Non-small Cell Lung Cancer","enrollment":420},{"nctId":"NCT03505320","phase":"PHASE2","title":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-06-29","conditions":"Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer","enrollment":143},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT07198633","phase":"PHASE1, PHASE2","title":"A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-10","conditions":"Advanced Prostate Cancer","enrollment":212}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Other Combination Anti-Cancer Therapies","genericName":"Other Combination Anti-Cancer Therapies","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a category descriptor for multiple combination anti-cancer therapies rather than a single drug, typically involving synergistic use of two or more oncologic agents. Used for Various solid tumors and hematologic malignancies (specific combinations vary by pipeline program).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}